Safety and efficacy of immune checkpoint inhibitors in advanced urological cancers with pre-existing autoimmune disorders: a retrospective international multicenter study

BACKGROUND: There is limited experience regarding the safety and efficacy of checkpoint inhibitors (CPI) in patients with autoimmune disorders (AD) and advanced urological cancers as they are generally excluded from clinical trials due to risk of exacerbations. METHODS: This multicenter retrospectiv...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Immunother Cancer
Main Authors: Martinez Chanza, Nieves, Xie, Wanling, Issa, Majd, Dzimitrowicz, Hannah, Tripathi, Abhishek, Beuselinck, Benoit, Lam, Elaine, Zakharia, Yousef, Mckay, Rana, Shah, Sumit, Mortazavi, Amir, R. Harrison, Michael, Sideris, Spyridon, Kaymakcalan, Marina D, Abou Alaiwi, Sarah, Nassar, Amin H, Nuzzo, Pier Vitale, Hamid, Anis, K Choueiri, Toni, C Harshman, Lauren
Formato: Artigo
Idioma:Inglês
Publicado em: BMJ Publishing Group 2020
Assuntos:
Clinical/Translational Cancer Immunotherapy
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7174076/
https://ncbi.nlm.nih.gov/pubmed/32217762
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2020-000538
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados